| Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer (NCT07759492) | Intergroupe Francophone de Cancerologie Thoracique | 2026-11-01 |
| Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease (NCT07420439) | Intergroupe Francophone de Cancerologie Thoracique | 2026-09-15 |
| Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma (NCT07234058) | Intergroupe Francophone de Cancerologie Thoracique | 2026-04-02 |
| Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (NCT06937905) | Intergroupe Francophone de Cancerologie Thoracique | 2026-02-06 |
| Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated (NCT06908993) | Intergroupe Francophone de Cancerologie Thoracique | 2025-12-09 |
| Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer (NCT06656598) | Intergroupe Francophone de Cancerologie Thoracique | 2025-11-07 |
| Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (NCT06840834) | Intergroupe Francophone de Cancerologie Thoracique | 2025-06-30 |
| A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (NCT06053099) | Intergroupe Francophone de Cancerologie Thoracique | 2024-01-22 |
| Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) (NCT05856695) | Intergroupe Francophone de Cancerologie Thoracique | 2023-11-17 |
| Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (NCT05781308) | Intergroupe Francophone de Cancerologie Thoracique | 2023-04-26 |
| Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) (NCT05200481) | Intergroupe Francophone de Cancerologie Thoracique | 2022-05-18 |
| De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (NCT05255302) | Intergroupe Francophone de Cancerologie Thoracique | 2022-05-02 |
| RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (NCT05285033) | Intergroupe Francophone de Cancerologie Thoracique | 2022-04-01 |
| RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC (NCT05273047) | Intergroupe Francophone de Cancerologie Thoracique | 2022-03-01 |
| RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) (NCT05154344) | Intergroupe Francophone de Cancerologie Thoracique | 2021-11-29 |
| Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) (NCT04621188) | Intergroupe Francophone de Cancerologie Thoracique | 2021-03-19 |
| BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation (NCT04775095) | Intergroupe Francophone de Cancerologie Thoracique | 2021-03-08 |
| Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC (NCT04920981) | Intergroupe Francophone de Cancerologie Thoracique | 2021-02-02 |
| ENCOrafenib With Binimetinib in bRAF NSCLC (NCT04526782) | Intergroupe Francophone de Cancerologie Thoracique | 2021-01-19 |
| Immunotherapy in Patient With Poor General Condition (NCT04108026) | Intergroupe Francophone de Cancerologie Thoracique | 2020-10-14 |
| Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (NCT04111705) | Intergroupe Francophone de Cancerologie Thoracique | 2020-08-05 |
| Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation (NCT04233021) | Intergroupe Francophone de Cancerologie Thoracique | 2020-07-16 |
| Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (NCT03977194) | Intergroupe Francophone de Cancerologie Thoracique | 2019-07-23 |
| Her2-positive Lung Cancer Treated With Dedicated Drug (NCT03845270) | Intergroupe Francophone de Cancerologie Thoracique | 2019-05-17 |
| Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib (NCT03727477) | Intergroupe Francophone de Cancerologie Thoracique | 2019-02-01 |
| Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NCT03591731) | Intergroupe Francophone de Cancerologie Thoracique | 2019-01-02 |
| Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (NCT03469960) | Intergroupe Francophone de Cancerologie Thoracique | 2018-05-02 |
| Immunotherapy by Nivolumab for HIV+ Patients (NCT03304093) | Intergroupe Francophone de Cancerologie Thoracique | 2017-10-19 |
| Immunotherapy as Second-line in Patient With Small Cell Lung Cancer (NCT03059667) | Intergroupe Francophone de Cancerologie Thoracique | 2017-03-13 |
| Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer (NCT03030131) | Intergroupe Francophone de Cancerologie Thoracique | 2017-01-12 |
| Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program (NCT02933346) | Intergroupe Francophone de Cancerologie Thoracique | 2016-09-01 |
| Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (NCT02716311) | Intergroupe Francophone de Cancerologie Thoracique | 2016-05-01 |
| Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (NCT02716272) | Intergroupe Francophone de Cancerologie Thoracique | 2016-03-24 |
| Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (NCT02727335) | Intergroupe Francophone de Cancerologie Thoracique | 2014-05-01 |
| Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer (NCT01850303) | Intergroupe Francophone de Cancerologie Thoracique | 2013-05-16 |
| Paclitaxel-bevacizumab in Advanced Lung Cancer (NCT01763671) | Intergroupe Francophone de Cancerologie Thoracique | 2013-05-01 |
| Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. (NCT01705184) | Intergroupe Francophone de Cancerologie Thoracique | 2012-12-01 |
| Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer (NCT01631136) | Intergroupe Francophone de Cancerologie Thoracique | 2012-07-01 |
| Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR (NCT01556191) | Intergroupe Francophone de Cancerologie Thoracique | 2012-05-15 |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings (NCT01700582) | Intergroupe Francophone de Cancerologie Thoracique | 2012-04-01 |
| French National Observatory of Patients With Thymic Epithelial Tumor (NCT02724696) | Intergroupe Francophone de Cancerologie Thoracique | 2012-01-01 |
| French Biological Observatory on Lung Cancer in Never Smokers (NCT01465854) | Intergroupe Francophone de Cancerologie Thoracique | 2011-11-01 |
| Chemotherapy for Lung Cancer in HIV-positive Patients (NCT01296113) | Intergroupe Francophone de Cancerologie Thoracique | 2011-05-01 |
| Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) (NCT01102231) | Intergroupe Francophone de Cancerologie Thoracique | 2010-03-01 |
| Bevacizumab in Extensive Small Cell Lung Cancer (NCT00930891) | Intergroupe Francophone de Cancerologie Thoracique | 2009-09-01 |
| TAilored Post-Surgical Therapy in Early Stage NSCLC (NCT00775385) | Intergroupe Francophone de Cancerologie Thoracique | 2009-04-01 |
| Adjuvant Pazopanib in Stage I NSCLC (NCT00775307) | Intergroupe Francophone de Cancerologie Thoracique | 2008-11-01 |
| Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (NCT00651456) | Intergroupe Francophone de Cancerologie Thoracique | 2008-02-01 |
| NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy (NCT00535275) | Intergroupe Francophone de Cancerologie Thoracique | 2007-09-01 |
| Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma (NCT00384826) | Intergroupe Francophone de Cancerologie Thoracique | 2006-09-01 |
| Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) (NCT00298415) | Intergroupe Francophone de Cancerologie Thoracique | 2006-03-01 |
| Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature (NCT00198380) | Intergroupe Francophone de Cancerologie Thoracique | 2005-04-01 |
| Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up (NCT00198341) | Intergroupe Francophone de Cancerologie Thoracique | 2005-01-01 |
| Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV (NCT00198393) | Intergroupe Francophone de Cancerologie Thoracique | 2004-11-01 |
| A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER. (NCT00198406) | Intergroupe Francophone de Cancerologie Thoracique | 2002-09-01 |
| Chemoradiotherapy of NSCLC Stage IIIB (NCT00198432) | Intergroupe Francophone de Cancerologie Thoracique | 2002-03-01 |
| Stage I/II NSCLC Perioperative Chemotherapy (NCT00198354) | Intergroupe Francophone de Cancerologie Thoracique | 2001-05-01 |